JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR

International Journal of Laboratory Hematology

Volumn 40, Issue 2, 2018, Pages 181-186

  Nystrand, C F ^a   Ghanima, W ^a,b   Waage, A ^c,d   Jonassen, C M ^a,e  

^a Østfold Hospital Trust   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

Author keywords

droplet digital PCR; JAK2 V617F; myeloproliferative neoplasms; serum

Indexed keywords

JANUS KINASE 2;

ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FALSE POSITIVE RESULT; GENE MUTATION; HUMAN; JAK2 GENE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MUTATIONAL LOAD; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; BLOOD; GENETICS; MUTATION; MYELOPROLIFERATIVE DISORDER; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION;

HUMANS; JANUS KINASE 2; METHODS; MUTATION; MYELOPROLIFERATIVE DISORDERS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 85034263238     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12762     Document Type: Article

References (27)

1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
2. Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010;3:323-337.
3. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer. 2009;115:3842-3847.
4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
5. Fontanelli G, Barate C, Ciabatti E, et al. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms. Int J Lab Hematol. 2015;37:766-773.
6. Lange T, Edelmann A, Siebolts U, et al. JAK2 p. V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica. 2013;98:722-728.
7. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow. Leukemia. 2008;22:194-195.
8. Takahashi K, Patel KP, Kantarjian H, et al. JAK2 p. V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013;122:3784-3786.
9. Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006;8:397-411. quiz 526.
10. Pinheiro LB, Coleman VA, Hindson CM, et al. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. Anal Chem. 2012;84:1003-1011.
11. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. Quantitation of targets for PCR by use of limiting dilution. Biotechniques. 1992;13:444-449.
12. Waterhouse M, Follo M, Pfeifer D, et al. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. Ann Hematol. 2016;95:739-744.
13. Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406:6499-6512.
14. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579-586.
15. Xue X, Teare MD, Holen I, Zhu YM, Woll PJ. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta. 2009;404:100-104.
16. Zhou J, Huang A, Yang XR. Liquid biopsy and its potential for management of hepatocellular carcinoma. J Gastrointest Cancer. 2016;47:157-167.
17. Kinugasa H, Nouso K, Miyahara K, et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. 2015;121:2271-2280.
18. Rustad EH, Coward E, Skytoen ER, et al. Monitoring of multiple myeloma by quantification of recurrent mutations in serum. Haematologica. 2017;102:1266-1272.
19. Zhu G, Ye X, Dong Z, et al. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. J Mol Diagn. 2015;17:265-272.
20. Kinugasa H, Nouso K, Tanaka T, et al. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer. 2015;112:1652-1655.
21. Ma W, Kantarjian H, Verstovsek S, et al. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006;134:341-343.
22. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
23. Sho S, Court CM, Kim S, et al. Digital PCR Improves Mutation Analysis in Pancreas Fine Needle Aspiration Biopsy Specimens. PLoS ONE. 2017;12:e0170897.
24. Kinz E, Leiherer A, Lang AH, Drexel H, Muendlein A. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR. Int J Lab Hematol. 2015;37:217-224.
25. Ma W, Kantarjian H, Zhang X, et al. Higher detection rate of JAK2 mutation using plasma. Blood. 2008;111:3906-3907.
26. Ma W, Kantarjian H, Zhang X, et al. Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology. Int J Lab Hematol. 2010;32:95-102.
27. Jeannot E, Becette V, Campitelli M, et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma. J Pathol Clin Res. 2016;2:201-209.